Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Overview
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Celldex Therapeutics Inc
Elsalys Biotech SA
F. Hoffmann-La Roche Ltd
Qurient Co Ltd
TamRx LLC
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit TYRO-3 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ri Oligonucleotide to Inhibit TYRO-3 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TYRO3 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AXL, MERTK and TYRO3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNC-3810A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kise Receptor TYRO3 (Tyrosine Protein Kise BYK or Tyrosine Protein Kise DTK or Tyrosine Protein Kise RSE or Tyrosine Protein Kise TIF or Tyrosine Protein Kise SKY or TYRO3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jul 22, 2019: Researchers unveil experimental compound to block therapeutic target in blood cancer
Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for Immunotherapy of Cancer’s 33rd annual meeting
Dec 29, 2017: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting
Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Celldex Therapeutics Inc, H2 2019
Pipeline by Elsalys Biotech SA, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Qurient Co Ltd, H2 2019
Pipeline by TamRx LLC, H2 2019
Dormant Projects, H2 2019